The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1690
ISSUE1690
November 27, 2023
Etrasimod (Velsipity) for Ulcerative Colitis
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Etrasimod (Velsipity) for Ulcerative Colitis
November 27, 2023 (Issue: 1690)
The oral sphingosine 1-phosphate (S1P) receptor
modulator etrasimod (Velsipity – Pfizer) has been
approved by the FDA for treatment of moderately to
severely active ulcerative colitis in adults. It is the
second oral S1P receptor modulator to be...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
